Tandem Diabetes Care (TNDM) R&D In Process (2022 - 2025)
Tandem Diabetes Care posted quarterly R&D In Process of -$17000.0 for Q4 2025, down 100.02% on a QoQ basis from $75.2 million in Q1 2025.
Tandem Diabetes Care (TNDM) has 3 years of R&D In Process data on file, last reported at -$17000.0 in Q4 2025.
- For the quarter ending Q4 2025, R&D In Process changed N/A year-over-year to -$17000.0; the trailing twelve-month figure through Mar 2026 stood at -$17000.0 (down 100.02% YoY), and the FY2025 full-year result was $75.2 million, changed N/A from the prior year.
- R&D In Process for Q4 2025 stood at -$17000.0, down from $75.2 million in the prior quarter.
- Across five years, R&D In Process topped out at $78.8 million in Q1 2023 and bottomed at -$17000.0 in Q4 2025.
- The 3-year median for R&D In Process is $31.0 million (2022), against an average of $37.0 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17,000.00 |
| Mar 31, 2025 | 75.22 Mn |
| Mar 31, 2023 | 78.75 Mn |
| Dec 31, 2022 | 23,000.00 |
| Sep 30, 2022 | 31.02 Mn |